Alphamab Oncology launches on-market share buyback of up to HK$ 80 million

• Alphamab Oncology authorized an on-market share buyback of up to HK$80 million, starting Aug. 28, 2026.
• Repurchases will be funded from existing cash, with the price capped at 5% above the prior five-day average closing price.
• Shares bought back may be canceled or held as treasury shares, depending on market conditions and capital management needs.
• No shares have been repurchased under the mandate as of the announcement date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12306708), on August 28, 2026, and is solely responsible for the information contained therein.